CD4 T-cell immunotherapy for chronic viral infections and cancer

Immunotherapy

Volumn 5, Issue 9, 2013, Pages 975-987

  Kamphorst, Alice O ^a   Ahmed, Rafi ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adoptive cell transfer; cancer; CD4 T cells; chronic infection; exhaustion; immunotherapy; PD 1

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL EXPANSION; CELL FUNCTION; DNA MODIFICATION; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; NEOPLASM; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION;

ADOPTIVE TRANSFER; ANIMALS; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; HUMANS; IMMUNITY, INNATE; NEOPLASMS; VIRUS DISEASES;

EID: 84883583943     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.91     Document Type: Review

References (99)

1. Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4( +) T cells in immunity to viruses. Nat. Rev. Immunol. 12(2), 136-148 (2012).
2. Muranski P, Restifo NP. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr. Opin. Immunol. 21(2), 200-208 (2009).
3. Wherry EJ. T cell exhaustion. Nat. Immunol. 12(6), 492-499 (2011).
4. Day CL, Kaufmann DE, Kiepiela P et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443(7109), 350-354 (2006).
5. Porichis F, Kwon DS, Zupkosky J et al. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood 118(4), 965-974 (2011).
6. Sester U, Presser D, Dirks J, Gartner BC, Kohler H, Sester M. PD-1 expression and IL-2 loss of cytomegalovirus- specific T cells correlates with viremia and reversible functional anergy. Am. J. Transplant. 8(7), 1486-1497 (2008).
7. Butler NS, Moebius J, Pewe LL et al. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat. Immunol. 13(2), 188-195 (2012).
8. Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell 138(1), 30-50 (2009).
9. Greenberg PD, Cheever MA, Fefer A. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J. Exp. Med. 154(3), 952-963 (1981).
10. Kahn M, Sugawara H, McGowan P et al. CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J. Immunol. 146(9), 3235-3241 (1991).
11. Surman DR, Dudley ME, Overwijk WW, Restifo NP. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J. Immunol. 164(2), 562-565 (2000).
12. Hunder NN, Wallen H, Cao J et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358(25), 2698-2703 (2008).
13. Aubert RD, Kamphorst AO, Sarkar S et al. Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proc. Natl Acad. Sci. USA 108(52), 21182-21187 (2011).
14. Smyk-Pearson S, Tester IA, Klarquist J et al. Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help. J. Virol. 82(4), 1827-1837 (2008).
15. Rosenberg ES, Billingsley JM, Caliendo AM et al. Vigorous HIV-1-specific CD4+ T-cell responses associated with control of viremia. Science 278(5342), 1447-1450 (1997).
16. Zhou Y, Callendret B, Xu D et al. Dominance of the CD4( +) T helper cell response during acute resolving hepatitis A virus infection. J. Exp. Med. 209(8), 1481-1492 (2012).
17. Matloubian M, Concepcion RJ, Ahmed R. CD4 + T cells are required to sustain CD8 + cytotoxic T-cell responses during chronic viral infection. J. Virol. 68(12), 8056-8063 (1994).
18. Zajac AJ, Blattman JN, Murali-Krishna K et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188(12), 2205-2213 (1998).
19. Bergthaler A, Flatz L, Verschoor A et al. Impaired antibody response causes persistence of prototypic T cell-contained virus. PLoS Biol. 7(4), e1000080 (2009).
20. Grakoui A, Shoukry NH, Woollard DJ et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 302(5645), 659-662 (2003).
21. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393(6684), 478-480 (1998).
22. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4 + T-helper and a T-killer cell. Nature 393(6684), 474-478 (1998).
23. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393(6684), 480-483 (1998).
24. Bourgeois C, Rocha B, Tanchot C. A role for CD40 expression on CD8 + T cells in the generation of CD8 + T cell memory. Science 297(5589), 2060-2063 (2002).
25. Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN. Chemokines enhance immunity by guiding naive CD8 + T cells to sites of CD4 + T cell-dendritic cell interaction. Nature 440(7086), 890-895 (2006).
26. Nakanishi Y, Lu B, Gerard C, Iwasaki A. CD8( +) T lymphocyte mobilization to virus-infected tissue requires CD4( +) T-cell help. Nature 462(7272), 510-513 (2009).
27. Blattman JN, Grayson JM, Wherry EJ, Kaech SM, Smith KA, Ahmed R. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 9(5), 540-547 (2003).
28. Lichterfeld M, Kaufmann DE, Yu XG et al. Loss of HIV-1-specific CD8 + T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4 + T cells. J. Exp. Med. 200(6), 701-712 (2004).
29. Frohlich A, Kisielow J, Schmitz I et al. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 324(5934), 1576-1580 (2009).
30. Elsaesser H, Sauer K, Brooks DG. IL-21 is required to control chronic viral infection. Science 324(5934), 1569-1572 (2009).
31. Yi JS, Du M, Zajac AJ. A vital role for interleukin-21 in the control of a chronic viral infection. Science 324(5934), 1572-1576 (2009).
32. Chevalier MF, Julg B, Pyo A et al. HIV-1-specific interleukin-21 + CD4 + T-cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J. Virol. 85(2), 733-741 (2011).
33. Sutherland AP, Joller N, Michaud M, Liu SM, Kuchroo VK, Grusby MJ. IL-21 Promotes CD8 + CTL activity via the transcription factor T-bet. J. Immunol. (2013).
34. Kao C, Oestreich KJ, Paley MA et al. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8 + T-cell responses during chronic infection. Nat. Immunol. 12(7), 663-671 (2011).
35. Bachmann MF, Hunziker L, Zinkernagel RM, Storni T, Kopf M. Maintenance of memory CTL responses by T helper cells and CD40-CD40 ligand: antibodies provide the key. Eur. J. Immunol. 34(2), 317-326 (2004).
36. Klein F, Halper-Stromberg A, Horwitz JA et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492(7427), 118-122 (2012).
37. Burton DR. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2(9), 706-713 (2002).
38. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10(5), 317-327 (2010).
39. Victora GD, Schwickert TA, Fooksman DR et al. Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter. Cell 143(4), 592-605 (2010).
40. Vinuesa CG, Cyster JG. How T cells earn the follicular rite of passage. Immunity 35(5), 671-680 (2011).
41. Victora GD, Nussenzweig MC. Germinal centers. Annu. Rev. Immunol. 30, 429-457 (2012).
42. Crotty S. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29, 621-663 (2011).
43. Reinhardt RL, Liang HE, Locksley RM. Cytokine-secreting follicular T cells shape the antibody repertoire. Nat. Immunol. 10(4), 385-393 (2009).
44. Fahey LM, Wilson EB, Elsaesser H, Fistonich CD, Mcgavern DB, Brooks DG. Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells. J. Exp. Med. 208(5), 987-999 (2011).
45. Petrovas C, Yamamoto T, Gerner MY et al. CD4 T follicular helper cell dynamics during SIV infection. J. Clin. Invest. 122(9), 3281-3294 (2012).
46. Hong JJ, Amancha PK, Rogers K, Ansari AA, Villinger F. Spatial alterations between CD4( +) T follicular helper, B, and CD8( +) T cells during simian immunodeficiency virus infection: T/B cell homeostasis, activation, and potential mechanism for viral escape. J. Immunol. 188(7), 3247-3256 (2012).
47. Lindqvist M, van Lunzen J, Soghoian DZ et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J. Clin. Invest. 122(9), 3271-3280 (2012).
48. Harker JA, Lewis GM, Mack L, Zuniga EI. Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection. Science 334(6057), 825-829 (2011).
49. Cubas RA, Mudd JC, Savoye AL et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat. Med. 19(4), 494-499 (2013).
50. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19, 65-91 (2001).
51. Marshall NB, Swain SL. Cytotoxic CD4 T cells in antiviral immunity. J. Biomed. Biotechnol. 954602 (2011).
52. Jellison ER, Kim SK, Welsh RM. Cutting edge: MHC class II-restricted killing in vivo during viral infection. J. Immunol. 174(2), 614-618 (2005).
53. Brown DM. Cytolytic CD4 cells: direct mediators in infectious disease and malignancy. Cell. Immunol. 262(2), 89-95 (2010).
54. Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, Ten Berge IJ. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4 + T cells in protection against CMV disease. Blood 101(7), 2686-2692 (2003).
55. Casazza JP, Betts MR, Price DA et al. Acquisition of direct antiviral effector functions by CMV-specific CD4 + T lymphocytes with cellular maturation. J. Exp. Med. 203(13), 2865-2877 (2006).
56. Brien JD, Uhrlaub JL, Nikolich-Zugich J. West Nile virus-specific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection. J. Immunol. 181(12), 8568-8575 (2008).
57. Brown DM, Lee S, Garcia-Hernandez Mde L, Swain SL. Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection. J. Virol. 86(12), 6792-6803 (2012).
58. Perez-Diez A, Joncker NT, Choi K et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109(12), 5346-5354 (2007).
59. Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330(17), 1185-1191 (1994).
60. Rooney CM, Smith CA, Ng CY et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345(8941), 9-13 (1995).
61. Heslop HE, Ng CY, Li C et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 2(5), 551-555 (1996).
62. Heslop HE, Slobod KS, Pule MA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115(5), 925-935 (2010).
63. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257(5067), 238-241 (1992).
64. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333(16), 1038-1044 (1995).
65. Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17(13), 4550-4557 (2011).
66. Hunziker L, Klenerman P, Zinkernagel RM, Ehl S. Exhaustion of cytotoxic T cells during adoptive immunotherapy of virus carrier mice can be prevented by B cells or CD4 + T cells. Eur J. Immunol. 32(2), 374-382 (2002).
67. Tishon A, Lewicki H, Rall G, Von Herrath M, Oldstone MB. An essential role for type 1 interferon-gamma in terminating persistent viral infection. Virology 212(1), 244-250 (1995).
68. Hui CK, Lie A, Au WY et al. A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood 106(2), 464-469 (2005).
69. Brodie SJ, Lewinsohn DA, Patterson BK et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat. Med. 5(1), 34-41 (1999).
70. Koenig S, Conley AJ, Brewah YA et al. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat. Med. 1(4), 330-336 (1995).
71. Paulos CM, Suhoski MM, Plesa G et al. Adoptive immunotherapy: good habits instilled at youth have long-term benefits. Immunol. Res. 42(1-3), 182-196 (2008).
72. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26(4), 332-342 (2003).
73. Topalian SL, Rivoltini L, Mancini M et al. Human CD4 + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl Acad. Sci. USA 91(20), 9461-9465 (1994).
74. Depontieu FR, Qian J, Zarling AL et al. Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proc. Natl Acad. Sci. USA 106(29), 12073-12078 (2009).
75. Sharkey MS, Lizée G, Gonzales MI, Patel S, Topalian SL. CD4( +) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Res. 64(5), 1595-1599 (2004).
76. Surh CD, Sprent J. Homeostasis of naive and memory T cells. Immunity 29(6), 848-862 (2008).
77. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T-cell response. Nat. Rev. Immunol. 12(4), 269-281 (2012).
78. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8 + T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118(1), 294-305 (2008).
79. Hale JS, Youngblood B, Latner DR et al. Distinct memory CD4 T Cells with commitment to T follicular helper- and T helper 1-cell lineages are generated after Acute viral infection. Immunity 38(4), 805-817 (2013).
80. Turtle CJ, Riddell SR. Genetically retargeting CD8 + lymphocyte subsets for cancer immunotherapy. Curr. Opin. Immunol. 23(2), 299-305 (2011).
81. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365(8), 725-733 (2011).
82. Kalos M, Levine BL, Porter DL et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3(95), 95ra73 (2011).
83. Brentjens RJ, Davila ML, Riviere I et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5(177), 177ra138 (2013).
84. Kochenderfer JN, Dudley ME, Feldman SA et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119(12), 2709-2720 (2012).
85. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat. Rev. Clin. Oncol. 10(5), 267-276 (2013).
86. Brentjens RJ, Riviere I, Park JH et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118(18), 4817-4828 (2011).
87. Levine BL, Bernstein WB, Aronson NE et al. Adoptive transfer of costimulated CD4 + T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat. Med. 8(1), 47-53 (2002).
88. Perez EE, Wang J, Miller JC et al. Establishment of HIV-1 resistance in CD4 + T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 26(7), 808-816 (2008).
89. Wilen CB, Wang J, Tilton JC et al. Engineering HIV-resistant human CD4 + T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog. 7(4), e1002020 (2011).
90. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008).
91. Barber DL, Wherry EJ, Masopust D et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077), 682-687 (2006).
92. Velu V, Titanji K, Zhu B et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458(7235), 206-210 (2009).
93. Goding SR, Wilson KA, Xie Y et al. Restoring immune function of tumor-specific CD4 + T cells during recurrence of melanoma. J. Immunol. (2013).
94. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012).
95. Lipson EJ, Sharfman WH, Drake CG et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin. Cancer Res. 19(2), 462-468 (2013).
96. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 2012).
97. Autologous T-cells genetically modified at the CCR5 gene by zinc finger nucleases SB-728 for HIV (zinc-finger).http://clinicaltrials.gov/show/ NCT00842634
98. Phase 1 Dose escalation study of autologous T-cells genetically modified at the CCR5 gene by zinc finger nucleases in HIV-infected patients.http:// clinicaltrials.gov/show/NCT01044654
99. Study of autologous T-cells genetically modified at the CCR5 gene by zinc finger nucleases in HIV-infected subjects.http://clinicaltrials.gov/show/ NCT01252641